NAGE

Niagen Bioscience, Inc. (NAGE) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Niagen Bioscience, Inc. is a global bioscience company focused on healthy aging, primarily through the commercialization of nicotinamide adenine dinucleotide (NAD+) precursors, specifically its proprietary ingredient Niagen®. The company operates through four segments: Consumer Products, Ingredients, Analytical Reference Standards and Services, and Pharmaceuticals. A significant strategic shift occurred during the quarter with the divestiture of the Analytical Reference Standards and Services segment.

Key Financial Metrics

Liquidity and Debt: The company holds $66.5 million in cash and cash equivalents. There are no borrowings outstanding under its $10.0 million line of credit. The company has a deferred consideration obligation of approximately $5.6 million related to patent rights acquired in late 2025.

Material Changes vs. Prior Period

• Segment Divestiture: On February 24, 2026, the company sold its Analytical Reference Standards and Services segment for approximately $6.0 million in cash, recognizing a $4.8 million gain on the sale. This gain significantly boosted net income despite a decline in core operating income.
• Operating Income Decline: Core operating income decreased from $4.8 million in Q1 2025 to $1.6 million in Q1 2026. This was driven by a 40% increase in General and Administrative (G&A) expenses (to $7.2 million) and a 19% increase in Sales and Marketing expenses (to $9.7 million), partially offset by revenue growth.
• Revenue Growth: Net sales increased 3% year-over-year. Consumer Products sales grew 4% to $22.4 million, and Ingredients sales grew 5% to $8.6 million. The Analytical segment sales dropped 48% due to the mid-quarter sale.
• Cash Flow Shift: Operating cash flow turned negative ($1.2 million used) compared to a positive $7.9 million in the prior year, primarily due to increased inventory levels ($3.6 million use) and higher trade receivables ($3.4 million use), alongside the absence of a prior-year credit loss recovery.

Guidance, Outlook, and Risks

Management Commentary: Management expects the divestiture to reduce operating complexity and concentrate revenue on higher-growth consumer and ingredient offerings. However, they noted that shared fixed costs previously allocated to the sold segment will now be absorbed by remaining operations, potentially impacting margins in the near term. The company anticipates sufficient liquidity for the next 12 months but may seek additional capital for long-term strategic objectives.

Legal and Regulatory Risks:

• Elysium Health Litigation: The company is appealing a district court judgment awarding Elysium Health approximately $9.2 million plus interest (totaling ~$10.4 million) regarding patent infringement. Management believes the court abused its discretion; no accrual has been recorded as the outcome is uncertain.
• FDA Litigation: The company filed a lawsuit against the FDA challenging its regulatory stance on nicotinamide mononucleotide (NMN). The FDA has filed a motion to dismiss.
• Thorne Research Lawsuit: Thorne Research filed a complaint alleging tortious interference and unfair competition. The company intends to defend vigorously; potential loss is currently indeterminable.
• Supplier Concentration: The company relies on a single supplier, W.R. Grace & Co., for its key raw material (NRC), creating supply chain risk.

Investor Verification Checklist

• Core Profitability: Verify the trend in operating income excluding the one-time $4.8 million gain on the segment sale to assess the sustainability of core operations.
• Working Capital Trends: Monitor the increase in trade receivables and inventory, which drove negative operating cash flow, to ensure collection and inventory turnover remain healthy.
• Legal Exposure: Track the status of the Elysium Health appeal, as a loss could result in a liability of approximately $10.4 million.
• Expense Management: Review the 40% increase in G&A expenses and 19% increase in Sales & Marketing to determine if these are one-time costs or a new baseline for the company.
• Supplier Dependency: Assess the terms and stability of the exclusive supply agreement with W.R. Grace & Co. for NRC.